肾移植围手术期醛固酮的变化与肾功能的关系研究

范连慧; 刘龙; 何龙; 毕晓军; 李健

doi:10.3969/j.issn.1674-7445.2016.02.010

肾移植围手术期醛固酮的变化与肾功能的关系研究

doi: 10.3969/j.issn.1674-7445.2016.02.010

110016 沈阳军区总医院泌尿外科

详细信息

通讯作者:
范连慧, Email:flhurology@sina.com

中图分类号: R617
计量
- 文章访问数: 59
- HTML全文浏览量: 36
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-08
- 网络出版日期: 2021-01-19
- 刊出日期: 2016-03-15

Analysis of relationship between aldosterone level changes and renal function during perioperative period of renal transplantation

Department of Urology, the General Hospital of Shenyang Military Region, Shenyang 110016, China

More Information

Corresponding author: Fan Lianhui, Email:flhurology@sina.com

摘要

摘要: 目的分析肾移植患者围手术期醛固酮与肾功能变化的关系, 从而初步探讨醛固酮在慢性移植肾肾病中的作用。方法选取2010年1月1日到2013年12月31日, 在沈阳军区总医院泌尿外科行同种异体肾移植患者共100例作为实验组, 根据肾移植术后30 d时Scr水平将实验组再分为A组(Scr≥133 μmol/L, 13例)和B组(Scr < 133 μmol/L, 87例)。另选取年龄在25~35岁之间身体健康的志愿者10名, 作为对照组。实验组在肾移植的当日(0 d)、移植术后1、7、15、30 d清晨抽血, 对照组在相应时段抽血, 测定血清醛固酮和Scr水平。结果肾移植当日, 实验组和对照组的Scr水平分别为(598±37)μmol/L和(75±5)μmol/L, 醛固酮水平分别为(0.26±0.06) ng/dl和(0.13±0.03) ng/dl, 两组比较差异均有统计学意义(P < 0.05)。与0 d同组比较, 术后30 d A组受者Scr水平降低, 差异有统计学意义(P < 0.05), 醛固酮水平变化不大, 差异无统计学意义(P > 0.05);术后30 d B组受者Scr和醛固酮水平均明显降低, 差异均有统计学意义(均为P < 0.05)。相关分析结果显示, 实验组的血清醛固酮与Scr的变化均呈正相关(r=0.85, P < 0.05)。结论肾移植术后Scr及醛固酮的变化趋势呈正相关, 初步认为醛固酮在介导移植肾损伤过程中发挥着一定的作用。
- 肾移植 /
- 醛固酮 /
- 血清肌酐 /
- 移植肾肾病
Abstract: Objective To investigate the relationship between changes of aldosterone level and renal function during perioperative period of renal transplantation and preliminarily discuss the role of aldosterone in chronic allograft nephropathy. Methods One hundred patients undergoing allogeneic renal transplantation in the Department of Urology of the General Hospital of Shenyang Military from January 1, 2010 to December 31, 2013 were assigned into the experimental group. According to the Scr levels measured at 30 d after renal transplantation, 100 patients were divided into groups A (Scr≥133 μmol/L, n=13) and B (Scr < 133 μmol/L, n=87). Ten healthy individuals aged 25-35 years were recruited into the control group. In the experimental group, blood sample was collected in the morning upon the day of renal transplantation (0 d), 1, 7, 15 and 30 d after renal transplantation. In the control group, blood sample was obtained at the same time points for measurement of aldosterone and Scr levels. Results On the day of renal transplantation, the Scr level in the experimental group was (598±37) μmol/L, significantly higher compared with (75±5) μmol/L in the control group (P < 0.05). The aldosterone level in the experimental group was (0.26±0.06) ng/dl, considerably higher than (0.13±0.03) ng/dl in the control group (P < 0.05). Compared with 0 d, the Scr levels of group A significantly decreased at postoperative 30 d (P < 0.05), whereas no statistical significance was noted in aldosterone levels between two time points (P > 0.05). In group B, both Scr and aldosterone levels were significantly decreased at postoperative 30 d (both in P < 0.05). Correlation analysis revealed that the serum level of aldosterone was positively correlated with Scr level changes (r=0.85, P < 0.05). Conclusions After renal transplantation, change of Scr level is positively correlated with aldosterone level alterations, probably suggesting that aldosterone plays a partial role in mediating injury of transplant kidney during renal transplantation.
- Renal transplantation /
- Aldosterone /
- Serum creatinine /
- Allograft nephropathy

HTML全文

表 1 A组和B组受者血清肌酐和醛固酮水平的比较

Table 1. Comparison of levels of serum creatinine and aldosterone of recipients between two groups(x±s)

组别	n	Scr(μmol/L)		醛固酮(ng/dl)
组别	n	0 d	术后30 d	0 d	术后30 d
A组	13	589±41	252±10^a	0.25±0.04	0.23±0.06
B组	87	602±52	95±9^{a, b}	0.26±0.03	0.15±0.02^{a, b}

下载: 导出CSV

参考文献(17)

[1]	Rezaee-Zavareh MS, Ajudani R, Ramezani Binabaj M, et al. Kidney allograft stone after kidney transplantation and its association with graft survival[J]. Int J Organ Transplant Med, 2015, 6(3):114-118. http://www.ncbi.nlm.nih.gov/pubmed/26306157
[2]	Asher J, Vasdev N, Wyrley-Birch H, et al. A prospective randomised paired trial of sirolimus versus tacrolimus as primary immunosuppression following non-heart beating donor kidney transplantation[J]. Curr Urol, 2014, 7(4):174-180. https://www.ncbi.nlm.nih.gov/pubmed/26195946
[3]	苏子庭, 李珍, 曾仲, 等.活体肾移植供肾肾小球滤过率对术后移植肾功能恢复的影响[J].器官移植, 2015, 6(5):331-334, 339. http://www.organtranspl.com/browse/detail/qkid/32/id/129.html Su ZT, Li Z, Zeng Z, et al. Influence of glomerular filtration rate of living donor on recovery of graft function after transplantation[J]. Organ Transplant, 2015, 6(5):331-334, 339. http://www.organtranspl.com/browse/detail/qkid/32/id/129.html
[4]	Te Riet L, van Esch JH, Roks AJ, et al. Hypertension:renin-angiotensin-aldosterone system alterations[J].Circ Res, 2015, 116(6):960-975. doi: 10.1161/CIRCRESAHA.116.303587
[5]	Singh P, Feld RI, Colombe BW, et al. Sensitization, pathologic, and imaging findings comparing symptomatic and quiescent failed renal allografts[J]. Clin Transplant, 2014, 28(12):1424-1432. doi: 10.1111/ctr.2014.28.issue-12
[6]	Daniel C, Vogelbacher R, Stief A, et al. Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis inchronic allograft nephropathy[J]. PLoS One, 2013, 8(12):e83846. doi: 10.1371/journal.pone.0083846
[7]	Sandhu JS, Kansal S, Bajwa GS, et al. Ocular changes in renal allograft recipients and patients of chronic kidney disease[J]. Saudi J Kidney Dis Transpl, 2014, 25(6):1285-1289. doi: 10.4103/1319-2442.144269
[8]	Vaidya A, Underwood PC, Hopkins PN, et al. Abnormal aldosterone physiology and cardiometabolic risk factors[J]. Hypertension, 2013, 61(4):886-893. doi: 10.1161/HYPERTENSIONAHA.111.00662
[9]	Bollag WB. Regulation of aldosterone synthesis and secretion[J]. Compr Physiol, 2014, 4(3):1017-1055.
[10]	Hart A, Jackson S, Kasiske BL, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy:post hoc analysis from the angiotensin Ⅱ blockade in chronic allograft nephropathy trial[J]. Transplantation, 2014, 97(10):1066-1071. doi: 10.1097/01.TP.0000440952.29757.66
[11]	Bernardi S, Toffoli B, Zennaro C, et al. Aldosterone effects on glomerular structure and function[J]. J Renin Angiotensin Aldosterone Syst, 2015, 16(4):730-738. doi: 10.1177/1470320315595568
[12]	范愈燕, 孙永新, 支楠, 等.醛固酮诱导大鼠肾脏衰老机制研究[J].中国临床药理学杂志, 2013, 29(1):42-44. http://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201301014.htm Fan YY, Sun YX, Zhi N, et al. Mechanism of aldosterone induced rat kidney senescence[J]. Chin J Clin Pharmacol, 2013, 29(1):42-44. http://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201301014.htm
[13]	Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia[J]. JAMA Intern Med, 2014, 174(3):347-354. doi: 10.1001/jamainternmed.2013.12700
[14]	Mavrakanas TA, Gariani K, Martin PY. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitoror angiotensin Ⅱ receptor blocker treatment:an emerging paradigm in diabetic nephropathy:a systematic review[J]. Eur J Intern Med, 2014, 25(2):173-176. doi: 10.1016/j.ejim.2013.11.007
[15]	BarıŞ N, Özpelit E, Doğan NB, et al. The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients[corrected][J]. Anadolu Kardiyol Derg, 2013, 13(3):245-250. https://www.ncbi.nlm.nih.gov/pubmed/23261803
[16]	Peng F, Su J, Lin J, et al. Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury:a prospective study and meta-analysis[J]. J Cardiovasc Pharmacol, 2015, 65(3):262-268. doi: 10.1097/FJC.0000000000000189
[17]	Huang LL, Nikolic-Paterson DJ, Ma FY, et al. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signaling[J]. Nephron Exp Nephrol, 2012, 120(4):e115-e122. doi: 10.1159/000339500